International Advisory and Monitoring Board

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

Retrieved on: 
Mercredi, décembre 7, 2022
RHO, BLA, Health, MTD, NR2E3, Security (finance), Retinitis pigmentosa, CEP290, DSMB, Hope, International Advisory and Monitoring Board, LCA, Risk, Biologics license application, Vaccine, FACS, Infection, Șaeș, Retina, Gene, Research, Public health, Leber congenital amaurosis, Patient, RP, Pharmaceutical industry, MD

MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study.

Key Points: 
  • “No serious adverse events (SAEs) related to OCU400 have been reported to date.”
    10 patients with NR2E3 and RHO gene mutations associated with RP have been dosed in the Phase 1/2 clinical trial to date.
  • Data from the MTD has the potential to navigate strategy for the planned Phase 3 study in the U.S. and other major markets.
  • The Company plans to file a Biologics License Application (BLA) for OCU400 in 2025.
  • Ocugen is committed to finding solutions for people with inherited retinal disease for whom no effective treatment options exist.

SignTime Announces Appointment of International Advisory Board

Retrieved on: 
Lundi, novembre 7, 2022
International Advisory and Monitoring Board, CEO, Bank, Region, Growth, Technology, Software as a service, Cisco Systems, Multimedia, Digital, Contract, Founder, Polycom, BNY Mellon, Management

TOKYO, Nov. 7, 2022 /PRNewswire/ -- SignTime , today announced the appointment of four senior executives to its International Advisory Board.

Key Points: 
  • TOKYO, Nov. 7, 2022 /PRNewswire/ -- SignTime , today announced the appointment of four senior executives to its International Advisory Board.
  • The company's advisory board provides strategic and technical advice to help support the growth of SignTime's business activities in Japan and the development of its overseas markets.
  • SignTime was founded in 2020 as a SaaS and web-based application that provides e-signature and digital contracting services.
  • "As we scale up our team to further drive our momentum in the Japan market, and accelerate our international expansion, now is an ideal time to announce our advisory board.

Paul Achleitner joins Hakluyt's International Advisory Board

Retrieved on: 
Jeudi, juillet 28, 2022
Hakluyt & Company, CEO, Government, CFO, Goldman Sachs, Bayer, International Advisory and Monitoring Board, Deutsche Bank, Financial services, Management, Hakluyt, Unilever, Allianz

LONDON, July 28, 2022 /PRNewswire/ -- Hakluyt, the strategic advisory firm for businesses and investors, has today announced that Professor Dr. Paul Achleitner has joined its International Advisory Board.

Key Points: 
  • LONDON, July 28, 2022 /PRNewswire/ -- Hakluyt, the strategic advisory firm for businesses and investors, has today announced that Professor Dr. Paul Achleitner has joined its International Advisory Board.
  • Varun Chandra, Hakluyt's managing partner, said: "I am delighted to welcome Paul to our International Advisory Board.
  • Niall FitzGerald KBE added: "All of us on the International Advisory Board are greatly looking forward to working with Paul.
  • Paul Achleitner commented: "It's an honour to have joined Hakluyt's International Advisory Board, and to have the opportunity to contribute to its fascinating work advising senior leaders across almost all sectors.

Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

Retrieved on: 
Lundi, juillet 25, 2022
Virus, Division, University, GLOBE, A Call for Unity, American Pediatric Society, Hijack, Drug discovery, CEO, SEC, International Advisory and Monitoring Board, Research, National Institute, COVID-19, Nature, NASDAQ, Virology, UAB, ISCB Senior Scientist Award, Gene therapy, Company, Senior advisor, Patient, List, Department, Annual report, National Institute of Allergy and Infectious Diseases, The Pediatric Infectious Disease Journal, Infection, RNA, Pharmaceutical industry, Enochian, Pediatrics, COVID

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Companys Senior Scientific Advisor.

Key Points: 
  • LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Companys Senior Scientific Advisor.
  • A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies.
  • "We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul.
  • "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in our research pipelines.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Lundi, juin 6, 2022
Psilocybin, Disorder, Organ transplantation, CSE, Company, Liver disease, Research, DSMB, Inflammation, Omicron, Therapy, RVV, Study, Coronavirus, FDA, Patient, GLOBE, Emergency Use Authorization, Infection, Acquisition, COVID-19, International Advisory and Monitoring Board, Autoimmune hepatitis, Ischemia, Drug development, Reperfusion injury, Orphan drug, Safety, Pharmaceutical industry, Delta, CBD

The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint.

Key Points: 
  • The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint.
  • The DSMB supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Jeudi, mai 26, 2022
Psilocybin, Company, Coronavirus, Patient, Infection, Study, DSMB, Disorder, Emergency Use Authorization, Autoimmune hepatitis, COVID-19, Reperfusion injury, Orphan drug, FDA, Research, CSE, RVV, Liver disease, Omicron, International Advisory and Monitoring Board, Safety, Drug development, Therapy, Inflammation, Acquisition, Organ transplantation, Ischemia, GLOBE, Pharmaceutical industry, CBD, Delta

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

Key Points: 
  • The FDA has agreed that the Company may unblind the pre-dose-selection data for the first 210 patients of the Study to further support the new primary endpoint.
  • The DSMB supported the continuation of the Study in its last meeting as there were no serious adverse events or safety concerns reported.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Lundi, avril 25, 2022
Psilocybin, CSE, Drug development, CEO, International Advisory and Monitoring Board, Liver disease, Organ transplantation, Biomedical Advanced Research and Development Authority, COVID-19, Research, RVV, Inflammation, GLOBE, Patient, Infection, DSMB, Development, Data analysis, Company, Ischemia, Safety, Disorder, Autoimmune hepatitis, Study, Coronavirus, BARDA, FDA, Disease, Acquisition, Orphan drug, Reperfusion injury, Therapy, Pharmaceutical industry, CBD, Revive

The Company has been in discussions with the Biomedical Advanced Research and Development Authority (BARDA) for Bucillamine to explore the potential of securing advanced development and possible commercial scale-up funding.

Key Points: 
  • The Company has been in discussions with the Biomedical Advanced Research and Development Authority (BARDA) for Bucillamine to explore the potential of securing advanced development and possible commercial scale-up funding.
  • Discussions surrounding Bucillamines attributes and clinical potential were determined to be relevant for consideration, which could provide support to the Companys current efforts.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Lundi, avril 11, 2022
Psilocybin, Company, Drug development, Therapy, Autoimmune hepatitis, RVV, Patient, Research, Ischemia, CEO, Inflammation, Quality of life, Omicron, Safety, Reperfusion injury, Orphan drug, Goal, Coronavirus, Liver disease, Study, Emergency Use Authorization, COVID-19, GLOBE, Disorder, Infection, Organ transplantation, FDA, Acquisition, Disease, International Advisory and Monitoring Board, CSE, Pharmaceutical industry, Revive, Delta, CBD

The Company has made efforts in determining the appropriate revised primary and secondary clinical endpoints for FDA consideration for potential Emergency Use Authorization.

Key Points: 
  • The Company has made efforts in determining the appropriate revised primary and secondary clinical endpoints for FDA consideration for potential Emergency Use Authorization.
  • In parallel, the Company will continue enrollment activities in the U.S. and Turkey and is still targeting Q2-2022 to meet the enrollment goals.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Altesa BioSciences Announces Scientific Advisory Board

Retrieved on: 
Lundi, février 28, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Princeton University Department of Chemistry, RNA, Drug development, COVID-19, Virology, GA, Gilead Sciences, Distinguishing, Coronavirus Scientific Advisory Board (Turkey), Chronic obstructive pulmonary disease, Department, HIV, Division, Therapy, Rhinovirus, Partnership, Board, University of North Carolina, University, Emory University School of Medicine, Safety, MS, Critical Care Medicine (journal), Drug discovery, Pulmonology, Collaboration, CEO, Emory University, Director, Chapel Hill, DSMB, Critical care, SAB, Neurosurgery, DRIVE, International Advisory and Monitoring Board, Patient, Doctor of Philosophy, Orthornavirae, Physician, NIH, Infection, FDA, COPD, Emtricitabine, Pharmaceutical industry, Pediatrics, Pharmacology, Medicine, Vaxart, Microbiology, Molnupiravir, Health, Enterovirus, MD

Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).

Key Points: 
  • Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).
  • Altesa BioSciences, Inc is a biopharmaceutical company based in Atlanta, GA focused on developing antivirals to addresses diseases of global importance.
  • In July 2021, Altesa in-licensed Vapendavir, a Phase 2 antiviral broadly active against enteroviruses, including rhinovirus, from Vaxart.
  • Altesa intends to progress Vapendavir into Phase 2b trial in the coming months for treatment of rhinovirus in at-risk populations.

Global Barite (Oil & Gas, Chemicals, Fillers) Market Size, Share & Trends Analysis & Forecast Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Lundi, novembre 8, 2021
Energy, Natural Resources, Mining, Minerals, Oil, Gas, Prospectors, Glass, Ceramic, MEA, Central, USD, Waterloo, CAGR, Barium, Ministry, Mineral, Investment, COVID-19, Oil, Latin America, USGS, Ministry of Petroleum and Mineral Resources, Rubber industry in Malaysia, Content development, NCDMB, International Advisory and Monitoring Board

The "Barite Market Size, Share & Trends Analysis Report By Application (Oil & Gas, Chemicals, Fillers), By Region (North America, Europe, Asia Pacific, Central & South America, MEA), And Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Barite Market Size, Share & Trends Analysis Report By Application (Oil & Gas, Chemicals, Fillers), By Region (North America, Europe, Asia Pacific, Central & South America, MEA), And Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global barite market size is expected to reach 1.59 billion by 2028 and is expected to expand at a CAGR of 3.7% from 2021 to 2028.
  • Rising investments in increasing offshore explorations in the oil and gas industry are anticipated to augment the market growth over the forecast period.
  • It is found in hydrothermal ore veins, sedimentary rocks like limestone, clay deposits, marine deposits, and cavities in igneous rock.